Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Double Hematological and Cardiologic Benefits of Autologous Stem Cell Transplantation in a Case of stage III B IgG Myeloma multiplex and Dilatative Cardiomyopathy – a Case Report

Double Hematological and Cardiologic Benefits of Autologous Stem Cell Transplantation in a Case... Abstract We present a case of a 51 year old multiple myeloma patient due to the complexity of his disease. After prior high dose therapy with cardiotoxic cytostatic drugs patient developed cardiac arrest due to a ventricular fibrillation. Cardiopulmonary resuscitation was successfully but the hematologist stopped the cytostatic treatment due to the high cardiac risk. The only way to control his myeloma was an autologous transplantation but this also had a very high cardiotoxic potential due to the high dose of Melphalan administered as conditioning treatment. We present the difficulties and the results of this complex case. It also arises the potential beneficial effects of the megadose of stem cells on the myocardium but this needs further studies. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png ARS Medica Tomitana de Gruyter

Double Hematological and Cardiologic Benefits of Autologous Stem Cell Transplantation in a Case of stage III B IgG Myeloma multiplex and Dilatative Cardiomyopathy – a Case Report

Loading next page...
 
/lp/de-gruyter/double-hematological-and-cardiologic-benefits-of-autologous-stem-cell-3xE2Lb3f0e
Publisher
de Gruyter
Copyright
Copyright © 2015 by the
ISSN
1841-4036
eISSN
1841-4036
DOI
10.1515/arsm-2015-0050
Publisher site
See Article on Publisher Site

Abstract

Abstract We present a case of a 51 year old multiple myeloma patient due to the complexity of his disease. After prior high dose therapy with cardiotoxic cytostatic drugs patient developed cardiac arrest due to a ventricular fibrillation. Cardiopulmonary resuscitation was successfully but the hematologist stopped the cytostatic treatment due to the high cardiac risk. The only way to control his myeloma was an autologous transplantation but this also had a very high cardiotoxic potential due to the high dose of Melphalan administered as conditioning treatment. We present the difficulties and the results of this complex case. It also arises the potential beneficial effects of the megadose of stem cells on the myocardium but this needs further studies.

Journal

ARS Medica Tomitanade Gruyter

Published: Nov 1, 2015

There are no references for this article.